See more : EnQuest PLC (ENQUF) Income Statement Analysis – Financial Results
Complete financial analysis of NervGen Pharma Corp. (NGENF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NervGen Pharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Helix BioPharma Corp. (HBPCF) Income Statement Analysis – Financial Results
- Kesko Oyj (KESKOA.HE) Income Statement Analysis – Financial Results
- Almunda Professionals N.V. (AMUND.AS) Income Statement Analysis – Financial Results
- Tu Yi Holding Company Limited (1701.HK) Income Statement Analysis – Financial Results
- City Steel Public Company Limited (CITY.BK) Income Statement Analysis – Financial Results
NervGen Pharma Corp. (NGENF)
About NervGen Pharma Corp.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 145.00K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 0.00 |
| Gross Profit | -145.00K | -115.11K | -42.63K | -39.65K | -38.22K | -19.76K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.05M | 16.61M | 6.87M | 6.16M | 6.45M | 780.40K | 0.00 |
| General & Administrative | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Cost & Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Interest Income | 550.07K | 201.40K | 29.42K | 18.85K | 98.83K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 514.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 55.04K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 12.89K |
| EBITDA | -17.72M | -22.71M | -12.77M | -11.16M | -9.83M | -1.34M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.78M | -22.82M | -12.87M | -11.19M | -9.86M | -1.36M | -11.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.61M | 2.30M | 84.65K | 9.74K | 98.83K | 0.00 | 1.07K |
| Income Before Tax | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.60K | -84.65K | -9.74K | -133.64K | -141.38K | -12.89K |
| Net Income | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -0.39 | -0.32 | -0.35 | -0.38 | -0.05 | 0.00 |
| EPS Diluted | -0.38 | -0.39 | -0.32 | -0.35 | -0.38 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
| Weighted Avg Shares Out (Dil) | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated...
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President &...
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive...
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN)...
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief...
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024...
NervGen Files Management Information Circular and Announces Board of Directors Transition
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) -...
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it...
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food...
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture...
Source: https://incomestatements.info
Category: Stock Reports